Yongping Zhao, Bo Yan, Meijuan Li, Bin Zhang, Yuan Liu, Jie Li, Ying Gao, Chengfeng Chen, Yifan Jing
Journal: Psychoneuroendocrinology 2025;177():107472
PMID: 40288014
Many patients with major depressive disorder (MDD) experience limited treatment effectiveness due to an incomplete understanding of its neurobiological underpinnings. This review integrates neuroimaging and genetic data to examine structural and functional brain changes in MDD, alongside their genetic bases. A PRISMA-guided systematic review of imaging transcriptomics over the past decade was conducted using PubMed and Web of Science. Studies included MRI scans of both MDD patients and healthy controls, as well as brain-wide gene expression data, excluding those that were purely meta-analytical, lacked spatial correlations, or involved transdiagnostic analyses. Of the 206 studies reviewed, 20 met the inclusion criteria. Consistent patterns across studies reveal that key biological processes-such as synaptic signaling, calcium ion binding, neurodevelopment, immune regulation, and neurotransmitter transport-play a central role in brain alterations associated with MDD. Additionally, our findings suggest that electroconvulsive therapy (ECT) may alleviate symptoms by modulating these shared pathways. This review underscores the link between brain changes in MDD and specific gene expression profiles, offering insights that could inform more targeted therapeutic approaches.
Copyright © 2025 Elsevier Ltd. All rights reserved.
Miscellaneous:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.